PetMed Express Inc. (NASDAQ:PETS) CEO Menderes Akdag sold 10,000 shares of the stock in a transaction on Monday, October 10th. The stock was sold at an average price of $21.00, for a total transaction of $210,000.00. Following the sale, the chief executive officer now owns 600,000 shares of the company’s stock, valued at approximately $12,600,000. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Menderes Akdag also recently made the following trade(s):

  • On Thursday, September 22nd, Menderes Akdag sold 10,000 shares of PetMed Express stock. The stock was sold at an average price of $20.75, for a total transaction of $207,500.00.

Shares of PetMed Express Inc. (NASDAQ:PETS) opened at 20.32 on Wednesday. The stock has a 50 day moving average of $20.41 and a 200 day moving average of $19.28. PetMed Express Inc. has a 1-year low of $15.61 and a 1-year high of $21.16. The firm has a market cap of $410.06 million, a PE ratio of 19.35 and a beta of 1.07.

PetMed Express (NASDAQ:PETS) last posted its earnings results on Monday, July 25th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. PetMed Express had a net margin of 9.09% and a return on equity of 25.97%. The business had revenue of $72.50 million for the quarter. During the same period in the previous year, the firm posted $0.29 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Equities research analysts anticipate that PetMed Express Inc. will post $1.11 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for PetMed Express (NASDAQ:PETS)

Several hedge funds and other institutional investors have recently bought and sold shares of the company. NEXT Financial Group Inc boosted its position in PetMed Express by 167.2% in the second quarter. NEXT Financial Group Inc now owns 5,354 shares of the company’s stock worth $100,000 after buying an additional 3,350 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in PetMed Express by 101.2% in the second quarter. BNP Paribas Arbitrage SA now owns 6,206 shares of the company’s stock worth $116,000 after buying an additional 3,121 shares during the last quarter. Royal Bank of Canada boosted its position in PetMed Express by 19.6% in the second quarter. Royal Bank of Canada now owns 6,423 shares of the company’s stock worth $120,000 after buying an additional 1,053 shares during the last quarter. Cutler Group LP boosted its position in PetMed Express by 832.0% in the second quarter. Cutler Group LP now owns 7,064 shares of the company’s stock worth $132,000 after buying an additional 8,029 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in PetMed Express during the second quarter worth approximately $143,000. 75.97% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of PetMed Express from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 11th. Credit Suisse Group AG reiterated a “sell” rating and set a $13.00 price target on shares of PetMed Express in a research note on Tuesday, August 16th.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

5 Day Chart for NASDAQ:PETS

Receive News & Stock Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related stocks with our FREE daily email newsletter.